Acheson ED, Bachrach CA & Wright FM (1960) Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatrica Neurologica Scandinavica Suppl. 147, 132–147.
Anderson O, Lygner P-E, Bergström T, Andersson M & Vahlne A (1993) Viral infections trigger multiple sclerosis relapses: A prospective seroepidemiological study. Journal of Neurology 240, 417–422.
Bates C, Cartlidge NEF, French JM, Jackson HJ, Nightenhale S, Shaw DA, Smith S, Woo E, Hawkins SA, Miller JH, Belin J, Conroy DM, Gill SK, Sidey M, Smith AD, Thompson RHS, Zilkha K, Gale M & Sinclair HM (1989) A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 52, 18–22.
Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M & Bouillon R (1995) Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1α,25(OH)2D3. Journal of Neuroimmunology 61, 151–160.
Cantorna MT, Hayes CE & DeLuca HF (1996) 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proceedings of the National Academy of Sciences USA 93, 7861–7864.
Cantorna MT, Humpal-Winter J & DeLuca HF (1999) Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. Journal of Nutrition 129, 1966–1971.
Cantorna MT, Woodward WD, Hayes CE & DeLuca HF (1998) 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and IL-4. Journal of Immunology 160, 5314–5319.
Chick H, Dalyell EJ, Hume M, Mackay HMM & Smith HH (1922) The etiology of rickets in infants: prophylactic and curative observations at the Vienna University Kinderklinik. Lancet i, 7–12.
Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V & Lindsay R (1998) Fracture history and bone loss in patients with MS. Neurology 51, 1161–1165.
Davenport CB (1922) Multiple sclerosis from the standpoint of geographic distribution and race. Archives of Neurology and Psychiatry 8, 51–58.
Ebers GC (1998) The pathogenesis of multiple sclerosis. European Journal of Neurology 5, Suppl. 2, S7–S8.
Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Gray T, Nelson R, Nicolle M & Brunet D (1986) A population-based twin study in multiple sclerosis. New England Journal of Medicine 315, 1638–1642.
Ebers GC & Dyment DA (1998) Genetics of multiple sclerosis. Seminars in Neurology 18, 295–299.
Ebers GC & Sadovnick AD (1994) The role of genetic factors in multiple sclerosis susceptibility. Journal of Neuroimmunology 54, 1–17.
EURODIAB Substudy 2 Study Group (1999) Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia 42, 51–54.
Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K & Tashiro K (1999) Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. Journal of Neurological Sciences 166, 47–52.
Geiger R (1965) The Climate Near the Ground, pp. 442–446. Cambridge, MA: Harvard University Press.
Goldberg P (1974 a) Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: Sunlight, dietary factors and epidemiology. International Journal of Environmental Studies 6, 19–27.
Goldberg P (1974 b) Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 2: Biochemical and Genetic Factors. International Journal of Environmental Studies 6, 121–129.
Goldberg P, Fleming MC & Picard EM (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Medical Hypotheses 21, 193–200.
Hammond SR, English DR & McLeod JG (2000) The age-range of risk of developing multiple sclerosis. Evidence from a migrant population in Australia. Brain 123, 968–974.
Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH & Whitfield GK (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. Journal of Endocrinology 154, 557–573.
Hayes CE, Cantorna MT & DeLuca HF (1997) Vitamin D and multiple sclerosis. Proceedings of the Society for Experimental Biology and Medicine 216, 21–27.
Hess AF (1929) Rickets, Osteomalacia and Tetany, pp. 38–61. Philadephia, PA: Lea & Febiger.
Hess AF & Unger LF (1921) Cure of infantile rickets by sunlight. Journal of the American Medical Association 39, 77–82.
Holick MF (1995) Environmental factors that influence the cutaneous production of vitamin D. American Journal of Clinical Nutrition 61, Suppl., 638S–645S.
Holick MF (1998) Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporosis International Suppl. 8, S24–S29.
Holick MF, Schnoes HK & DeLuca HF (1971) Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proceedings of the National Academy of Sciences USA 68, 803–804.
Inobe JI, Chen Y & Weiner HL (1996) In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis. Annals of the New York Academy of Sciences 778, 390–392.
Johns LD, Flanders KC, Ranges GE & Sriram S (1991) Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. Journal of Immunology 147, 1792–1796.
Kurland LT (1952) The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada. American Journal of Hygiene 55, 457–476.
Kurtzke JF (1967) On the fine structure of the distribution of multiple sclerosis. Acta Neurologica Scandinavica 43, 257–282.
Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA & Thorbecke GJ (1991) Protective effect of transforming growth factor b1 on experimental autoimmune diseases in mice. Proceedings of the National Academy of Sciences USA 88, 2918–2921.
Lemire JM & Archer DC (1991) 1,25-Dihydroxyvitamin D3 suppresses the in vivo induction of murine experimental autoimmune encephalomyelitis. Journal of Clinical Investigation 87, 1103–1107.
Limburg CC (1950) Geographic distribution of multiple sclerosis and its estimated prevalence in the US. Proceedings of the Association for Research into Nervous Diseases 28, 15–24.
McDermott MF, Ramachandran A, Ogunkolade BW, Aganna E, Curtis D, Boucher BJ, Snehalatha C & Hitman GA (1997) Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 40, 971–975.
Malabanan A, Veronikis IE & Holick MF (1998) Redefining vitamin D insufficiency. Lancet 351, 805–806.
Nashold FE, Miller DJ & Hayes CE (2000) 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 103, 171–179.
Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V & Popjak G (1971) 1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine. Science 173, 51–54.
Noseworthy JH (1999) Progress in determining the causes and treatment of multiple sclerosis. Nature 399, A40–A47.
Nieves J, Cosman F, Herbert J, Shen V & Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44, 1687–1692.
Olitsky PK & Yager RH (1949) Experimental disseminated encephalomyelitis in white mice. Journal of Experimental Medicine 90, 213–223.
Panitch HS (1994) Influence of infection on exacerbations of multiple sclerosis. Annals of Neurology 36, S25–S28.
Pratt RTC, Compston ND & McAlpine D (1951) The familial incidence of multiple sclerosis and its significance. Brain 74, 191–232.
Presthus J (1960) Report on the multiple sclerosis investigations in West Norway. Acta Psychiatrica Neurologica Scandinavica Suppl. 147, 88–92.
Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS & McFarlin DE (1991) Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. Journal of Immunology 146, 3012–3017.
Sibley WA, Bamford CR & Clark K (1985) Clinical viral infections and multiple sclerosis. Lancet i, 1313–1315.
Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC and the Canadian Collaborative Study Group (2000) Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Neurology 54, 729–732.
Swank RL, Lerstad O, Strøm A & Backer J (1952) Multiple sclerosis in rural Norway: Its geographic and occupational incidence in relation to nutrition. New England Journal of Medicine 246, 721.
Ulett G (1948) Geographic distribution of multiple sclerosis. Diseases of the Nervous System 9, 342.
Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. American Journal of Clinical Nutrition 69, 842–856.
Velluz L & Amiard G (1949) Chimie organique-equilibre de reaction entre precalciferol et calciferol (Organic chemistry-balance of reaction between precalciferol and calciferol). Comptes Rendus de l'Academie des Sciences 228, 853–855.
Webb AR, Kline L & Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. Journal of Clinical Endocrinology and Metabolism 67, 373–378.
Westlund K (1970) Distribution and mortality time trend of multiple sclerosis and some other diseases of Norway. Acta Neurologica Scandinavica 46, 455–483.